Filing Details
- Accession Number:
- 0001225208-24-004692
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-01 18:55:43
- Reporting Period:
- 2024-04-01
- Accepted Time:
- 2024-04-01 18:55:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1099800 | Edwards Lifesciences Corp | EW | Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) | 364316614 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1446989 | B. Scott Ullem | One Edwards Way Irvine CA 92614 | Cvp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-04-01 | 7,255 | $36.75 | 26,329 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-04-01 | 868 | $95.51 | 25,461 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-04-01 | 6,387 | $94.81 | 19,074 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Acquire) | Disposition | 2024-04-01 | 7,255 | $0.00 | 7,255 | $36.75 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
7,250 | 2018-05-11 | 2024-05-10 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 266,318 | Indirect | By Trust |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023.
- This transaction was executed in multiple trades at prices ranging from $94.38 to $95.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.